Effect of the DPP-4 inhibitor, saxagliptin on glucose variability in type 2 diabetes patients with Chronic kidney disease - Effect of saxagliptin on glucose variability in type 2 diabetes patients with CKD

ihon University Itabashi Hospital0 个研究点目标入组 26 人开始时间: 2017年4月1日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1. Patients who have history of hypersensitivity to saxagliptin or the other dpp-4 inhibitors 2. Patients who have history of administration of incretin-related drugs within 4 weeks 3. Patients who changed anti-diabetic drugs, diet thrapy or exercise thrapy within 4 weeks 4. Patients who have end stage renal disease undergoing maintenance dialysis, or after renal transplantation 5. Patients who have history of severe ketosis, diabetic coma, or precoma within 6 months 6. Patients who have history of cancer within 5 years 7. Patients who have liver disfunction with AST or ALT>=3 x upper limit of normal 8. Patients who experienced severe traumatotherapy requiring surgery or surgery with general anesthesia within 6 months 9. Women who is pregnant or planned to become pregnant 10. Patients who are considered not eligible for the study by the attending doctor due to other reasons

发起方

ihon University Itabashi Hospital